"Everyone is very excited about the potential of these therapies to treat a variety of diseases. Increasing the access to them will be very important and part of that will be making them the standard of care or frontline therapies. Today, many of them are kind of third to fifth line and we're seeing those move upstream," Motlagh told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.
Motlagh argues that to achieve that standard of care the benefit of CGTs must be demonstrated, as well as increasing the access to them across the ecosystem.
Watch the video below to learn more.